Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeremiah Harnett is active.

Publication


Featured researches published by Jeremiah Harnett.


Bioorganic & Medicinal Chemistry Letters | 1999

BN 80927: A NOVEL HOMOCAMPTOTHECIN WITH INHIBITORY ACTIVITIES ON BOTH TOPOISOMERASE I AND TOPOISOMERASE II

Olivier Lavergne; Jeremiah Harnett; Alain Rolland; Christophe Lanco; Laurence Lesueur-Ginot; Danièle Demarquay; Marion Huchet; Hélène Coulomb; Dennis Bigg

BN 80927, a novel homocamptothecin derivative, inhibits both topoisomerase I and topoisomerase II mediated DNA relaxation and shows pronounced cytotoxicity against HT29, SKOV-3, DU145 and MCF7 human tumor cell lines.


Bioorganic & Medicinal Chemistry Letters | 2002

Novel lipoic acid analogues that inhibit nitric oxide synthase.

Jeremiah Harnett; Michel Auguet; Isabelle Viossat; Christine Dolo; Dennis Bigg; Pierre-E. Chabrier

The synthesis and biological activity of novel lipoic acid analogues are reported. Lipoic acid and structural homologues coupled to arylthiophene amidine via carboxamide linkers are metabolic antioxidants capable of protecting neuronal cells against glutamate cytotoxicity, preventing loss of intracellular glutathione, and inhibit nitric oxide synthase.


Bioorganic & Medicinal Chemistry Letters | 2003

Novel inhibitors of neuronal nitric oxide synthase with potent antioxidant properties

Serge Auvin; Michel Auguet; Edith Navet; Jeremiah Harnett; Isabelle Viossat; Jocelyne Schulz; Dennis Bigg; Pierre-E. Chabrier

A series of hybrid compounds possessing an nNOS pharmacophore linked to an antioxidant fragment has been synthesized. Among them, compound 8d, a propofol derivative, displayed the greatest dual potencies against nNOS (IC(50)=0.12 microM) and lipid peroxidation (IC(50)=0.4 microM) accompanied with e/nNOS selectivity (67.5). This shows that nNOS was able to accommodate very bulky groups such as di-tert-butyl or di-iso-propyl phenol in its active site.


Journal of Medicinal Chemistry | 1998

Homocamptothecins : Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues

Olivier Lavergne; Laurence Lesueur-Ginot; Francesc Pla Rodas; Philip G. Kasprzyk; Jacques Pommier; Danièle Demarquay; Gregoire Prevost; Gerard Ulibarri; Alain Rolland; § Anne-Marie Schiano-Liberatore; Jeremiah Harnett; Dominique Pons; and José Camara; Dennis Bigg


Bioorganic & Medicinal Chemistry Letters | 2004

Phenolic thiazoles as novel orally-active neuroprotective agents

Jeremiah Harnett; Véronique Roubert; Christine Dolo; Christelle Charnet; Brigitte Spinnewyn; Sylvie Cornet; Alain Rolland; Jean-Gregoire Marin; Dennis Bigg; Pierre-E. Chabrier


Archive | 2000

5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors

De Lassauniere Pierre-Etienne Chabrier; Jeremiah Harnett; Dennis Bigg; Jacques Pommier; Jacques Lannoy; Anne-Marie Liberatore; Christophe Thurieau


Archive | 2007

Derivatives of heterocycles with 5 members, their preparation and their use as medicaments

Pierre-Etienne Chabrier de Lassauniere; Jeremiah Harnett; Dennis Bigg; Anne-Marie Liberatore; Jacques Pommier; Jacques Lannoy; Christophe Thurieau


Archive | 1999

Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same

Serge Auvin; Pierre-Etienne Chabrier de Lassauniere; Jeremiah Harnett; Dominique Pons; Gerard Ulibarri


Archive | 2001

Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them

Pierre Etienne Chabrier De Lassauniere; Serge Auvin; Dennis Bigg; Michel Auguet; Jeremiah Harnett


Archive | 1998

Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same

Serge Auvin; Jeremiah Harnett; Dennis Bigg; De Lassauniere Pierre-Etienne Chabrier

Collaboration


Dive into the Jeremiah Harnett's collaboration.

Researchain Logo
Decentralizing Knowledge